The Clinical Trial for Evaluation of Efficacy and Safety of DWP05195 in Postherpetic Neuralgia: Double-blind, Placebo-controlled, Randomized, Multi-center, Exploratory Clinical Trial

Daewoong Pharmaceutical Co. LTD.0 sites140 target enrollmentMarch 2012

ConditionsPostherpetic Neuralgia

InterventionsDWP05195 Control

DrugsDWP05195 Control

Overview

Phase: Phase 2
Intervention: DWP05195
Conditions: Postherpetic Neuralgia
Sponsor: Daewoong Pharmaceutical Co. LTD.
Enrollment: 140
Primary Endpoint: Endpoint change from the baseline after administered 8 weeks mean pain score based on the Numerical pain Rating Scale(NPRS) from the subject's daily pain diary
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate efficacy, safety of administered DWP05195 in Postherpetic Neuralgia.

Registry

clinicaltrials.gov

Start Date

March 2012

End Date

December 2013

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Daewoong Pharmaceutical Co. LTD.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or Female subjects aged 20 to 80 years
•Subjects with symptoms of neuropathic pain associated with postherpetic neuralgia(PHN).
•Subjects must have pain present for \> 3 months after healing of the acute herpes zoster skin rash.

Exclusion Criteria

•Other severe pain that may potentially confound pain assessment.
•Subjects with symptoms of neuropathic pain applied Medical Equipment
•Within 2 years: Subjects were diagnosed with cancer

Arms & Interventions

Treatment B

Intervention: DWP05195

Treatment C

Intervention: DWP05195

Treatment A

Intervention: DWP05195

Treatment D

Intervention: Control

Outcomes

Primary Outcomes

Endpoint change from the baseline after administered 8 weeks mean pain score based on the Numerical pain Rating Scale(NPRS) from the subject's daily pain diary

Time Frame: 8 weeks